VistaGen Therapeutics

VTGN

Market cap $89M

Overview Fund Activity

2.90 USD

-0.01

0.34%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

2.88

-0.02

0.69%

1 day

-0.34%

5 days

-18.77%

1 month

-14.71%

3 months

21.85%

6 months

2.84%

Year to date

-12.65%

1 year

-6.45%

5 years

-85.41%

10 years

-97.65%

About: Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Employees: 57

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

499% more call options, than puts

Call options by funds: $437K | Put options by funds: $73K

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

64% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 11

6% more funds holding

Funds holding: 48 [Q1] → 51 (+3) [Q2]

2.1% less ownership

Funds ownership: 55.24% [Q1] → 53.14% (-2.1%) [Q2]

22% less capital invested

Capital invested by funds: $39M [Q1] → $30.3M (-$8.74M) [Q2]

See Fund Rankings

Financial journalist opinion

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry Conference. The Company will also host one-on-one meetings.

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Joshua S. Prince - Chief Operating Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K.

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

The Motley Fool

Vistagen (VTGN) Q1 R&D Expense Jumps 54%

Vistagen (VTGN) Q1 R&D Expense Jumps 54%

Vistagen (VTGN) Q1 R&D Expense Jumps 54%

Zacks Investment Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.35 per share a year ago.

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a corporate update. “We had another productive quarter, advancing key programs across our pipeline,” said Shawn Singh, Presid.

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a.

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen to Present at the BTIG Virtual Biotechnology Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be lives.

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, has earned two prestigious workplace honors in 2025, reinforcing its commitment to employee well-being and a strong, values-driven culture. For the third consecutive year, Vistagen received Mental Health America's Platinum Bell Sea.

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead the evaluation of strategic opportunities to advance Vistagen's pherine platform toward potential commercial la.

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K. Singh - President, CEO & Director Conference Call Participants Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Lin Tsai - Jefferies LLC, Research Division Myles Robert Minter - William Blair & Company L.L.C.

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™